Disclosures for "Impact of Baseline Sleep Disturbances on Pimavanserin Response in Parkinson’s Disease Psychosis: A Post Hoc Analysis"
-
Dr. Chrones has received personal compensation for serving as an employee of Acadia Pharmaceuticals.
-
Dr. Becerril has received personal compensation for serving as an employee of Acadia Pharmaceuticals. Dr. Becerril has stock in Acadia Pharmaceuticals.
-
Dr. Zhang has nothing to disclose.
-
Dr. Feng has nothing to disclose.
-
Dr. Brunson has received personal compensation for serving as an employee of Acadia Pharmaceuticals. Dr. Brunson has stock in Acadia Pharmceuticals.
-
Andrew Krystal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axsome Therapeutics, Abbvie, Big Health, Eisai, Evecxia, Harmony Biosciences, Idorsia, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences, Neumora, Neurawell, Otsuka Pharmaceuticals, Sage, Takeda. Andrew Krystal has stock in Neurawell, Big Health. The institution of Andrew Krystal has received research support from Alkermes; Janssen Pharmaceuticals, Axsome Pharmaceutics, Attune, Eisai, Harmony, Neumora; Neurocrine Biosciences, Reveal Biosensors, The Ray and Dagmar Dolby Family Fund, Weill Institute for Neurosciences, and the National Institutes of Health.